Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 15, 1963 - Issue 6
Submit an article Journal homepage
6
Views
74
CrossRef citations to date
0
Altmetric
Original Article

Selective Inhibition in Human Pregnancy Blood of Urokinase Induced Eibrinolysis

P. Brakman James F. Mitchell Foundation, Institute for Medical Research, Washington 15, DC, USA
&
T. Astrup James F. Mitchell Foundation, Institute for Medical Research, Washington 15, DC, USA
Pages 603-609 | Received 30 Jul 1963, Published online: 13 May 2010

Citations (74)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Birger Åstedt. (1974) Fibrinolytic Inhibitors in Human Retroplacental Blood. Acta Obstetricia et Gynecologica Scandinavica 53:3, pages 227-229.
Read now
S. Thorsen. (1973) The Inhibition of Tissue Plasminogen Activator and Urokinase-Induced Fibrinolysis by Some Natural Proteinase Inhibitors and by Plasma and Serum from Normal and Pregnant Subjects. Scandinavian Journal of Clinical and Laboratory Investigation 31:1, pages 51-59.
Read now
Birger Åstedt. (1972) Fibrinolytic Activity of Veins in the Puerperium. Acta Obstetricia et Gynecologica Scandinavica 51:4, pages 325-328.
Read now
Birger Astedt. (1972) On Fibrinolysis: A. In Pregnancy, Labour, Puerperium and During Treatment with Sex Hormones B. In Human Ontogenesis and in Human Organ Culture. Acta Obstetricia et Gynecologica Scandinavica 51:sup18, pages 1-45.
Read now
O. S. Lauritsen. (1969) The Fibrinolytic Enzyme System of Human Blood Plasma in Pregnancy. Scandinavian Journal of Clinical and Laboratory Investigation 23:3, pages 191-196.
Read now
O. S. Lauritsen. (1968) Urokinase Inhibitor in Human Plasma. Scandinavian Journal of Clinical and Laboratory Investigation 22:4, pages 314-321.
Read now
O. S. Lauritsen. (1966) Studifs on the Inhibition of Plasmin Caseinolysis by Human Serum and a Metmod for the Assay of Inhibiting Activity. Scandinavian Journal of Clinical and Laboratory Investigation 18:1, pages 73-79.
Read now

Articles from other publishers (67)

Nicola J. Mutch & Robert L. Medcalf. (2023) The fibrinolysis renaissance. Journal of Thrombosis and Haemostasis 21:12, pages 3304-3316.
Crossref
Gael B. Morrow & Nicola J. Mutch. (2022) Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1). Seminars in Thrombosis and Hemostasis 49:03, pages 305-313.
Crossref
A N Nicolaides, C T Clark, R D Thomas & J D Lewis. (1976) Fibrinolytic activator in the endothelium of the veins of the lower limb. British Journal of Surgery 63:11, pages 881-884.
Crossref
Markus Pihusch, Verena Pihusch & Ernst Holler. (2005) Plasminogen activator inhibitor-1: a review Plasminogen-Aktivator-Inhibitor-1: eine Übersicht. LaboratoriumsMedizin 29:6, pages 403-411.
Crossref
Michael J. Pugia & John A. Lott. (2005) Pathophysiology and diagnostic value of urinary trypsin inhibitors. Clinical Chemistry and Laboratory Medicine (CCLM) 43:1, pages 1-16.
Crossref
K L KaplanT MatherL DeMarcoS Solomon. (1989) Effect of fibrin on endothelial cell production of prostacyclin and tissue plasminogen activator.. Arteriosclerosis: An Official Journal of the American Heart Association, Inc. 9:1, pages 43-49.
Crossref
I. Lecander, I.M. Nilsson & B. Åstedt. (1988) Depression of plasminogen activator activity during pregnancy by the placental inhibitor PAI 2. Fibrinolysis 2:3, pages 165-167.
Crossref
B. Åstedt, I. Lecander & T. Ny. (1987) The placental type plasminogen activator inhibitor, PAI 2. Fibrinolysis 1:4, pages 203-208.
Crossref
R.D. Ye, T.C. Wun & J.E. Sadler. (1987) cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta.. Journal of Biological Chemistry 262:8, pages 3718-3725.
Crossref
R. Lottenberg & D.C. Willis. (1986) The rapid inhibition of urokinase by plasma from pregnant women at risk for abruptio placenta. Thrombosis Research 44:6, pages 807-815.
Crossref
Ingegerd Lecander & B. Åstedt. (2008) Isolation of a new specific plasminogen activator in hibitor from pregnancy plasma. British Journal of Haematology 62:2, pages 221-228.
Crossref
Inga Marie Nilsson, P. Felding, Ingegerd Lecander, Christina Lennér & B. Åstedt. (2008) Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. British Journal of Haematology 62:2, pages 215-220.
Crossref
Markku Seppälä, Eeva-Marja Rutanen, Jon E. Siiteri, Torsten Wahlström, Riitta Koistinen, Rauni Pietilä & Hans Bohn. (1983) IMMUNOLOGIC AND BIOLOGICAL PROPERTIES AND CLINICAL SIGNIFICANCE OF PLACENTAL PROTEINS PP5 AND PP12. Annals of the New York Academy of Sciences 417:1 Oncodevelopme, pages 368-382.
Crossref
S.Shaukat Husain, Victor Gurewich & Boguslaw Lipinski. (1983) Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Archives of Biochemistry and Biophysics 220:1, pages 31-38.
Crossref
Derek OgstonDerek Ogston. 1983. The Physiology of Hemostasis. The Physiology of Hemostasis 141 193 .
Derek OgstonDerek Ogston. 1983. The Physiology of Hemostasis. The Physiology of Hemostasis 343 360 .
F.K. Beller & C. Ebert. (1982) The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. European Journal of Obstetrics & Gynecology and Reproductive Biology 13:3, pages 177-197.
Crossref
J.E. Siiteri, R. Koistinen, H.T. Salem, H. Bohn & M. Seppälä. (1982) Placental protein 5 is related to blood coagulation and fibrinolytic systems. Life Sciences 30:22, pages 1885-1891.
Crossref
M. Uszyński, W. Majczyńska & T. Koźmińska. (1980) Measurement of euglobulin fibrinolysis time in women with retarded fetal development. European Journal of Obstetrics & Gynecology and Reproductive Biology 11:3, pages 147-155.
Crossref
M. Pandolfi & E. Lantz. (1979) Partial purification and characterization of keratokinase, the fibrinolytic activator of the cornea. Experimental Eye Research 29:5, pages 563-571.
Crossref
N. Gersel-Pedersen. (1979) Inhibitors of fibrinolysis in saliva after oral surgery measured by enzymic and immunological methods. International Journal of Oral Surgery 8:3, pages 212-221.
Crossref
Hau C. Kwaan. (1979) Fibrinolysis—A perspective. Progress in Cardiovascular Diseases 21:5, pages 397-403.
Crossref
F. Brosstad. (1979) Fibrinolysis of soluble and polymerized DES-AA/DES-AABB fibrin compared to fibrinogenolysis in buffer and in fibrinogen-boosted serum. Evidence that plasminogen activators are responsible for preferential degradation of polymerized fibrin. Thrombosis Research 15:3-4, pages 497-504.
Crossref
Nobuo Aoki. (1979) Natural inhibitors of fibrinolysis. Progress in Cardiovascular Diseases 21:4, pages 267-286.
Crossref
Lars Holmberg, Ingegerd Lecander, Bengt Persson & Birger Åstedt. (1978) An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. Biochimica et Biophysica Acta (BBA) - General Subjects 544:1, pages 128-137.
Crossref
F. Duckert. 1978. Fibrinolytics and Antifibrinolytics. Fibrinolytics and Antifibrinolytics 209 237 .
Nicolas E. Stathakis, Theofanis C. Economopoulos, Antony G. Papayannis & Demetrios Thomopoulos. (1977) Platelet function, blood coagulation and fibrinolysis in beh�et's syndrome. Blut 34:3, pages 215-222.
Crossref
Tage Astrup, David Tovi & Preben Kok. (1975) A new experimental model of physiological thrombolysis. Thrombosis Research 7:3, pages 493-496.
Crossref
A. N. Nicolaides & Ian Gordon-Smith. 1975. Thromboembolism. Thromboembolism 205 225 .
R. Aschauer, F. Holzknecht & S. Platzer. (1973) Endogene Fibrinolyseinhibitoren bei LebercirrhosenEndogenous inhibitors of fibrinolytic activity in liver cirrhosis. Klinische Wochenschrift 51:23, pages 1170-1172.
Crossref
Simone Silberman, Maria B. Bernik, Elizabeth V. Potter & Hau C. Kwaan. (2008) Effects of Ancrod (Arvin) in Mice: Studies of Plasma Fibrinogen and Fibrinolytic Activity. British Journal of Haematology 24:1, pages 101-113.
Crossref
Hau C. Kwaan. (1973) Inhibitors of fibrinolysis. Thrombosis Research 2:1, pages 31-40.
Crossref
Haruo Hisazumi & Katsuji Fukushima. (1973) A study on fibrinolysis in experimental bladder tumors. Urological Research 1:4, pages 186-191.
Crossref
P. Damani, D. Macintosh, Ila Patel, Hansa Patel, W. L. Stafford & A. G. Shaper. (2005) SERUM LIPIDS AND FIBRINOLYTIC ACTIVITY IN PREGNANT AFRICAN, ASIAN AND EUROPEAN WOMEN IN UGANDA. BJOG: An International Journal of Obstetrics & Gynaecology 79:12, pages 1095-1098.
Crossref
Hau C. Kwaan. (1972) Disorders of Fibrinolysis. Medical Clinics of North America 56:1, pages 163-176.
Crossref
Tage Astrup & Sixtus Thorsen. (1972) The Physiology of Fibrinolysis. Medical Clinics of North America 56:1, pages 153-162.
Crossref
ANNEMARIE SIEGEL-RALSTON & T. ASTRUP. (1971) Previously Undescribed Fibrinolysis Inhibitor in Human Blood. Nature New Biology 234:49, pages 180-181.
Crossref
J D Cash. (2016) Fibrinolysis. Proceedings of the Royal Society of Medicine 64:9, pages 926-927.
Crossref
Hau C. Kwaan & Nibha Suwanwela. (1971) Inhibitors of Fibrinolysis in Platelets in Polycythaemia Vera and Thrombocytosis. British Journal of Haematology 21:3, pages 313-322.
Crossref
Frank A. Manning, Agnes Wodzicki, Lynda Dunbar & Ashley T. Coopland. (1971) The fibrinolytic system in late pregnancy, labor, and the early puerperium. American Journal of Obstetrics and Gynecology 110:7, pages 900-907.
Crossref
P. M. Mannucci, R. Stabilini, R. Bragotti, B. Marasini & A. Agostoni. (1971) Enzymatic and immunochemical determination of plasminogen and plasmin in different physiological and pathological states. Journal of Clinical Pathology 24:3, pages 228-233.
Crossref
Ulla Hedner & Birger Astedt. (2011) Studies on Fibrinolytic Inhibitors During Pregnancy. Acta Obstetricia et Gynecologica Scandinavica 50:1, pages 99-103.
Crossref
HAU.C. KWAAN. 1971. The Circulating Platelet. The Circulating Platelet 395 413 .
W. Auerswald, W. Doleschel & E. Zweym�ller. (1971) Uroprotein excretion in neonates and infants. Zeitschrift f�r Kinderheilkunde 109:3, pages 262-270.
Crossref
P. Brakman, J. Snyder, E. S. Henderson & T. Astrup. (2008) Blood Coagulation and Fibrinolysis in Acute Leukaemia. British Journal of Haematology 18:2, pages 135-146.
Crossref
Pieter Brakman, Aquiles J. Sobrero & Tage Astrup. (1970) Effects of different systemic contraceptives on blood fibrinolysis. American Journal of Obstetrics and Gynecology 106:2, pages 187-192.
Crossref
U. Bleyl. 1970. Intensivtherapie beim septischen Schock. Intensivtherapie beim septischen Schock 15 44 .
M. Uszyński & R. Uszyński-Folejewska. (1969) Plasminogen activator and urokinase inhibitor in myometrium, placenta, and amniotic fluid. American Journal of Obstetrics and Gynecology 105:7, pages 1041-1043.
Crossref
Johan Ygge. (1969) Changes in blood coagulation and fibrinolysis during the puerperium. American Journal of Obstetrics and Gynecology 104:1, pages 2-12.
Crossref
Pieter Brakman. 1995. Metabolic Effects of Gonadal Hormones and Contraceptive Steroids. Metabolic Effects of Gonadal Hormones and Contraceptive Steroids 619 634 .
D.G. Woodfield, S.K. Cole & J.D. Cash. (1968) Impaired fibrinolytic response to exercise stress in normal pregnancy. American Journal of Obstetrics and Gynecology 102:3, pages 440-446.
Crossref
Fritz K. Beller, Gordon W. Douglas, Robert H. Morris & Alan J. Johnson. (1968) The fibrinolytic enzyme system in pregnancy. American Journal of Obstetrics and Gynecology 101:5, pages 587-592.
Crossref
T. Astrup. (2006) COMPARATIVE STUDIES OF SOME ANTIFIBRINOLYTIC AGENTS AND PROTEINASE INHIBITORS * . Annals of the New York Academy of Sciences 146:2, pages 601-611.
Crossref
A. G. Shaper, D.T.M. & H. Jill Kear, Ch.B. J. Kyobe & D. Njama. (2005) THE PLATELET COUNT, PLATELET ADHESIVENESS AND AGGREGATION AND THE MECHANISM OF FIBRINOLYTIC INHIBITION IN PREGNANCY AND THE PUERPERIUM. BJOG: An International Journal of Obstetrics & Gynaecology 75:4, pages 433-441.
Crossref
TAKEHIKO KAWANO, KAZUO MORIMOTO & YAHIRO UEMURA. (1968) Urokinase Inhibitor in Human Placenta. Nature 217:5125, pages 253-254.
Crossref
F. Spöttl, F. Holzknecht & H. Braunsteiner. (1968) Inhibitors of the plasminogen-activation in patients with primary “Carbohydrate-induced” hypertriglyceridemia. Journal of Atherosclerosis Research 8:5, pages 821-826.
Crossref
. 1968. Natural Proteinase Inhibitors. Natural Proteinase Inhibitors 121 151 .
M. Hilden, C. J. Amris & J. Starup. (2011) The Haemostatic Mechanism In Oral Contraception. Acta Obstetricia et Gynecologica Scandinavica 46:4, pages 562-571.
Crossref
Inga Marie Nilsson & Stig Kuuander. (2011) Coagulation And Fibrinolytic Studies During Pregnancy 1 . Acta Obstetricia et Gynecologica Scandinavica 46:3, pages 273-285.
Crossref
C. J. Amris & J. Starup. (2011) The Coagulation Mechanism in Oral Contraception. Acta Obstetricia et Gynecologica Scandinavica 46:1, pages 78-91.
Crossref
PIETER BRAKMAN, EMILE R. MOHLERJR.JR. & TAGE ASTRUP. (2009) A Group of Patients with Impaired Plasma Fibrinolytic System and Selective Inhibition of Tissue Activator‐Induced Fibrinolysis. Scandinavian Journal of Haematology 3:5, pages 389-398.
Crossref
P. Brakman, O. K. Albrechtsen & T. Astrup. (2008) A Comparative Study of Coagulation and Fibrinolysis in Blood from Normal Men and Women. British Journal of Haematology 12:1, pages 74-85.
Crossref
Donald P. Goldstein, Pieter Brakman & John R. Marshall. (1966) The plasma fibrinolytic system in patients with trophoblastic disease and undelivered hydatidiform mole. American Journal of Obstetrics and Gynecology 94:1, pages 21-28.
Crossref
Pieter Brakman. (1966) The fibrinolytic system in human blood during pregnancy. American Journal of Obstetrics and Gynecology 94:1, pages 14-20.
Crossref
A.G. Shaper, D.M. Macintosh, C.M. Evans & J. Kyobe. (1965) FIBRINOLYSIS AND PLASMINOGEN LEVELS IN PREGNANCY AND THE PUERPERIUM. The Lancet 286:7415, pages 706-708.
Crossref
Pieter Brakman & Allan E. King. (1965) The fibrinolytic system in blood after retention of a dead fetus and during normal labor. American Journal of Obstetrics and Gynecology 92:2, pages 221-226.
Crossref
Pieter Brakman & Tage Astrup. (1964) EFFECTS OF FEMALE HORMONES, USED AS ORAL CONTRACEPTIVES, ON THE FIBRINOLYTIC SYSTEM IN BLOOD. The Lancet 284:7349, pages 10-12.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.